Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.

Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM and 5 more

Show all authors

Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC

Chinese medical journal1 Feb 2013Cited by 19 (Europe PMC)

PMID23422107DOI10.3760/cma.j.issn.0366-6999.20121626PepBankPUB-23422107

Publisher page PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, rhPTH increased lumbar BMD more than elcatonin at all reported assessments.
In plain wordsIn women with osteoporosis, rhPTH increased lumbar bone density more than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD
Study
n = 453
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Lumbar BMD increase
4.3%
rhPTH at 6 months
Lumbar BMD increase
1.9%
elcatonin at 6 months
Lumbar BMD increase
6.8%
rhPTH at 12 months
Lumbar BMD increase
2.7%
elcatonin at 12 months
Lumbar BMD increase
9.5%
rhPTH at 18 months
Lumbar BMD increase
2.9%
elcatonin at 18 months
Source sentences
Summary
rhPTH (1-34) increased lumbar BMD significantly more than did elcatonin after 6, 12, and 18 months of treatment (4.3% vs. 1.9%, 6.8% vs. 2.7%, 9.5% vs. 2.9%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210701
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, rhPTH increased serum BSAP more than elcatonin at all reported assessments.
In plain wordsIn women with osteoporosis, rhPTH increased a bone formation marker more than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum BSAP
Study
n = 453
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Serum BSAP change
93.7%
rhPTH at 6 months
Serum BSAP change
−3.6%
elcatonin at 6 months
Serum BSAP change
117.8%
rhPTH at 12 months
Serum BSAP change
−4.1%
elcatonin at 12 months
Serum BSAP change
49.2%
rhPTH at 18 months
Serum BSAP change
−5.8%
elcatonin at 18 months
Source sentences
Summary
There were larger increases in bone turnover markers in the rhPTH (1-34) group than those in the elcatonin group after 6, 12, and 18 months (serum bone-specific alkaline phosphatase (BSAP) 93.7% vs. -3.6%; 117.8% vs. -4.1%; 49.2% vs. -5.8%, P < 0.01;
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210703
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, rhPTH increased urinary CTX/Cr more than elcatonin at all reported assessments.
In plain wordsIn women with osteoporosis, rhPTH increased a urinary bone turnover marker more than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary CTX/Cr
Study
n = 453
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Urinary CTX/Cr change
250%
rhPTH at 6 months
Urinary CTX/Cr change
−29.5%
elcatonin at 6 months
Urinary CTX/Cr change
330%
rhPTH at 12 months
Urinary CTX/Cr change
−41.4%
elcatonin at 12 months
Urinary CTX/Cr change
273%
rhPTH at 18 months
Urinary CTX/Cr change
−10.6%
elcatonin at 18 months
Source sentences
Summary
urinary C-telopeptide/creatinine (CTX/Cr) 250.0% vs. -29.5%; 330.0% vs. -41.4%, 273.0% vs. -10.6%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210704
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, rhPTH and elcatonin produced similar pain relief.
In plain wordsIn women with osteoporosis, rhPTH and elcatonin produced similar pain relief.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePain relief
Study
n = 453
Comparator
Elcatonin
Outcome group
Pain · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Source sentences
Summary
rhPTH (1-34) showed similar effect of pain relief as elcatonin.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210705
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, clinical fracture incidence did not differ significantly between rhPTH and elcatonin.
In plain wordsIn women with osteoporosis, fracture rates did not differ significantly between rhPTH and elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeClinical fractures
Study
n = 453
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Clinical fracture incidence
3.2%
rhPTH
Clinical fracture incidence
5.36%
elcatonin
Source sentences
Summary
The incidence of clinical fractures was 5.36% (6/112) in elcatonin group and 3.2% (11/341) in rhPTH (1-34) group (P = 0.303).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210706
06HumanRandomized controlled trialSafety outcome
In postmenopausal women with osteoporosis, rhPTH and elcatonin were well tolerated.
In plain wordsIn women with osteoporosis, rhPTH and elcatonin were well tolerated.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTolerability
Study
n = 453
Outcome group
Adverse events · Whole body
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210707
07HumanRandomized controlled trialSafety outcome
In women with osteoporosis, pruritus was more frequent with rhPTH than elcatonin.
In plain wordsIn women with osteoporosis, itching was more frequent with rhPTH than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePruritus
Study
n = 453
Comparator
Elcatonin
Outcome group
Adverse events · Skin and wound
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Pruritus incidence
8.2%
rhPTH
Pruritus incidence
2.7%
elcatonin
Source sentences
Summary
Pruritus (8.2% vs. 2.7%, P = 0.044) and redness of injection site (4.4% vs. 0, P = 0.024) were more frequent in rhPTH (1-34).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210710
08HumanRandomized controlled trialSafety outcome
In women with osteoporosis, injection site redness was more frequent with rhPTH than elcatonin.
In plain wordsIn women with osteoporosis, injection site redness was more frequent with rhPTH than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseInjection site redness
Study
n = 453
Comparator
Elcatonin
Outcome group
Adverse events · Skin and wound
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Injection site redness
4.4%
rhPTH
Injection site redness
0%
elcatonin
Source sentences
Summary
Pruritus (8.2% vs. 2.7%, P = 0.044) and redness of injection site (4.4% vs. 0, P = 0.024) were more frequent in rhPTH (1-34).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210711
09HumanRandomized controlled trialSafety outcome
In women with osteoporosis, nausea/vomiting was less frequent with rhPTH than elcatonin.
In plain wordsIn women with osteoporosis, nausea and vomiting were less frequent with rhPTH than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNausea/vomiting
Study
n = 453
Comparator
Elcatonin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Nausea/vomiting incidence
6.2%
rhPTH
Nausea/vomiting incidence
16.1%
elcatonin
Source sentences
Summary
Nausea/vomiting (16.1% vs. 6.2%, P = 0.001) and hot flushes (7.1% vs. 0.6%, P < 0.001) were more common in elcatonin group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210712
10HumanRandomized controlled trialSafety outcome
In women with osteoporosis, hot flushes were less frequent with rhPTH than elcatonin.
In plain wordsIn women with osteoporosis, hot flushes were less frequent with rhPTH than elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseHot flushes
Study
n = 453
Comparator
Elcatonin
Outcome group
Adverse events · Whole body
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Hot flush incidence
0.6%
rhPTH
Hot flush incidence
7.1%
elcatonin
Source sentences
Summary
Nausea/vomiting (16.1% vs. 6.2%, P = 0.001) and hot flushes (7.1% vs. 0.6%, P < 0.001) were more common in elcatonin group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210713
11HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, rhPTH increased femoral neck BMD after 18 months.
In plain wordsIn women with osteoporosis, rhPTH increased femoral neck bone density compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 341
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Femoral neck BMD increase
2.6%
rhPTH at 18 months
Source sentences
Summary
There was only a small but significant increase of femoral neck BMD after 18 months (2.6%, P < 0.01) in rhPTH groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The incidence of clinical fractures was 5.36% (6/112) in elcatonin group and 3.2% (11/341) in rhPTH (1-34) group (P = 0.303).
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210702
12HumanRandomized controlled trialSafety outcome
In women receiving rhPTH, transient hypercaluria occurred without clinical symptoms.
In plain wordsIn women receiving rhPTH, increased urinary calcium was temporary and caused no clinical symptoms.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercaluria
Study
n = 341
Outcome group
Adverse events · Kidney and urinary
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Hypercaluria incidence
9.4%
rhPTH
Source sentences
Summary
Hypercaluria (9.4%) and hypercalcemia (7.0%) in rhPTH (1-34) group were transient and caused no clinical symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
The incidence of clinical fractures was 5.36% (6/112) in elcatonin group and 3.2% (11/341) in rhPTH (1-34) group (P = 0.303).
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210708
13HumanRandomized controlled trialSafety outcome
In women receiving rhPTH, transient hypercalcemia occurred without clinical symptoms.
In plain wordsIn women receiving rhPTH, increased blood calcium was temporary and caused no clinical symptoms.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercalcemia
Study
n = 341
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 µg daily · 18 monthsAs given in this study (human).
Measurements
Hypercalcemia incidence
7%
rhPTH
Source sentences
Summary
Hypercaluria (9.4%) and hypercalcemia (7.0%) in rhPTH (1-34) group were transient and caused no clinical symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
The incidence of clinical fractures was 5.36% (6/112) in elcatonin group and 3.2% (11/341) in rhPTH (1-34) group (P = 0.303).
Summary · context
A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months.
Report a problemFND-2342210709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.